skip to main content
Give

Sara Rogers

Sara Rogers
Sara Rogers, PharmD, BCPS

Clinical Assistant Professor of Pharmacy Practice

Contact

Texas A&M Irma Lerma Rangel School of Pharmacy
1010 W. Ave. B
Kingsville, TX 78363
sararogers@tamu.edu
Phone: 979.436.0286

Biography

Sara Rogers serves as Clinical Assistant Professor of Precision Medicine and Ambulatory Care at Irma Lerma Rangel College of Pharmacy, Texas A&M University and Clinical Specialist at Texas A&M Physicians Clinic. She co-founded the American Society of Pharmacovigilance, where she led the Society’s clinical, research and educational initiatives. Rogers co-led the formation of the Pharmacogenomics Access and Reimbursement Coalition and collaboratively developed the Coalition’s research agenda to understand the payment and policy landscape for pharmacogenetics testing and its role in disparities in patient access. Rogers serves as an organizational member of the NIH National Human Genomics Research Institute Inter-Society Coordinating Committee and develops educational resources to help practitioners navigate coverage for pharmacogenetics testing. Her research track record reveals a long-standing goal of informing policy and practice. Dr. Rogers has served as co-investigator for a pilot study to identify ethical values and priorities related to pharmacogenomics. Her research focuses extensively on patient access to and reimbursement for pharmacogenetics testing. Rogers co-led the formation of the Standardizing Laboratory Practices in Pharmacogenomics (STRIPE) Collaborative Community, a public-private multidisciplinary initiative to develop consensus-based industry standards for pharmacogenetics testing.

Prior to serving in these roles, Rogers was an Ambulatory Treatment Center pharmacist at MD Anderson Cancer Center where she led team-based research projects to optimize workflow and screening protocols throughout the division of pharmacy.

Education and Training

  • University of Houston College of Pharmacy, Doctor of Pharmacy, 2012
  • The University of Texas at Austin, Bachelor of Arts in Biology, 2008

Professional Certifications

  • Board Certified Pharmacotherapy Specialist, Board of Pharmacy Specialties

Research Interests

  • Design of health policies informed by communities’ ethical values and priorities
  • Advancement of medication literacy in underserved communities
  • Advancement of genetics literacy for practitioners
  • Identification of novel genetic associations affecting medication response
  • Development of consensus-based industry standards for pharmacogenetics testing

Teaching Interests

  • Pharmacogenomics
  • Medication Therapy Management

Awards, Recognition and Service

  • Member, American Society of Clinical Oncology (ASCO)
  • Member, American Society of Health System Pharmacists (ASHP)
  • Board of Directors, American Society of Pharmacovigilance (ASP)
  • Member, Clinical Pharmacogenomics Implementation Consortium (CPIC)
  • Member, Pharmacogenomics, Working Group, NIH NHGRI Intersociety Coordinating Committee (ISCC)
  • Chair, Pharmacogenomics Access & Reimbursement Coalition (PARC)
  • Co-lead, Society of Physician Entrepreneurs (SoPE)

Representative Publications

Determeyer P, Crowder J, O'Mahony E, Esquivel B, Atwal H, Atwal PS, Rogers SL. Application of the community dialogues method to identify ethical values and priorities related to pharmacogenomics. Pharmacogenomics. 2021 Jul;22(11):693-701.

Rogers SL, Patrinos GP, Mitropoulou C, Formea CM, Shawn Jones J, Brown BG. Conference report: inaugural Pharmacogenomics Access & Reimbursement Symposium. Pharmacogenomics J. 2021 Oct;21(5):622-624. 

Rogers SL, Keeling NJ, Giri J, Gonzaludo N, Jones JS, Glogowski E, Formea CM. PARC report: a health-systems focus on reimbursement and patient access to pharmacogenomics testing. Pharmacogenomics. 2020 Jul;21(11):785-796.  

Mitropoulou C, Litinski V, Kabakchiev B, Rogers SL, P Patrinos G. PARC report: health outcomes and value of personalized medicine interventions: impact on patient care. Pharmacogenomics. 2020 Jul;21(11):797-807.  

Eichmeyer J, Rogers SL, Formea CM, Giri J, Jones JS, Schnettler E, Schmidlen T, Glogowski E, Kurz RN. PARC report: a perspective on the state of clinical pharmacogenomics testing. Pharmacogenomics. 2020 Jul;21(11):809-820.  

Parker BM, Rogers SL, Lymperopoulos A. Clinical pharmacogenomics of carvedilol: the stereo-selective metabolism angle. Pharmacogenomics. 2018 Sep 1;19(14):1089-1093.